ACE2 and COVID-19: Some preclinical studies have suggested that RAAS inhibitors may increase ACE2 (functional receptor for SARS-CoV-2) expression, raising concerns regarding safety in patients with COVID-19; however, the data remain anecdotal, and no clinical studies have evaluated the effects of RAAS inhibitors in COVID-19.